Abstract
Objective
To evaluate the efficacy and safety of galcanezumab in patients with migraine in a real-world setting in Japan.
Background
Galcanezumab is the first anti-calcitonin gene-related peptide monoclonal antibody approved in Japan. To the best of our knowledge, no real-world studies on galcanezumab have been published in any international journal from Japan.
Methods
We retrospectively examined patients with migraine who received three doses of galcanezumab between August 2021 and February 2022 at the Keio University Hospital. We assessed changes in monthly migraine days, responder rate, and migraine-associated and premonitory symptoms. We also investigated injection site reactions and adverse events.
Results
Fifty-two patients received three doses of galcanezumab during the study period. Compared with those at baseline, the monthly migraine days decreased by 5.9 days (95% confidence interval, 4.2–7.7) at 3 months. The 50% responder rate was 61.5% at 3 months. A total of 64.9%, 50.0%, and 63.9% of patients showed improvement in the severity of photophobia, phonophobia, and nausea/vomiting, respectively. Premonitory symptoms without subsequent headache were reported in 62.5% of patients. Moreover, injection site reaction was the most common adverse event (34.6%).
Conclusion
This study revealed the efficacy and safety of galcanezumab for migraineurs in Japan. Galcanezumab also improved migraine-associated symptoms. However, despite a reduction in headaches, premonitory symptoms without subsequent headache were reported in > 50% of the patients at 3 months.
Supplementary Information
The online version contains supplementary material available at 10.1186/s12883-022-03041-1.
Keywords: Galcanezumab, Migraine, Real-world evidence, Associated symptoms, Premonitory symptoms
Background
Migraine is a neurological disorder with a high prevalence and burden on patients [1, 2]. Migraine-preventive treatment has improved dramatically with the development of calcitonin gene-related peptide (CGRP)-targeted drugs [3].
Clinical studies have indicated the efficacy and safety of galcanezumab, an anti-CGRP monoclonal antibody, in patients with episodic migraine (EM) and chronic migraine (CM) [4, 5]. Galcanezumab is the first anti-CGRP monoclonal antibody approved in Japan (January 2021). Data on CGRPmAb clinical trials is limited for Asian populations compared to Western populations. In the pivotal global phases 2 and 3 trials of galcanezumab, Asians comprised only a small proportion of the total population [6–8]. Although clinical trials of galcanezumab focusing solely on Asians have recently been reported [4], yet there exists a need for further observing the drug’s effect among Asians population [9].
Criteria for the administration of galcanezumab differ between Japan and other countries. In Japan, galcanezumab can be used for patients with ≥ 4 migraine days per month and for those who have undergone treatment with at least one migraine-preventive drug (lomerizine, propranolol, or valproate) with ineffectiveness, intolerance, or strong concern about side effects [10]. Onabotulinumtoxin A—a globally used drug for chronic migraine—is not approved in Japan [11–14].
Real-world studies have recently reported the efficacy and safety of galcanezumab in Europe, the United States, and South Korea [9, 15–19]. However, to the best of our knowledge, no real-world studies from Japan on galcanezumab have been published in any international journal. Differences in race or criteria for the use of galcanezumab may cause differences in results between Japanese studies and those from other countries; thus, it is also necessary to study the efficacy and safety of galcanezumab in the real-world setting in Japan.
Migraineurs experience headaches and several associated symptoms (nausea, vomiting, photophobia, and phonophobia) during migraine. Moreover, migraineurs have premonitory symptoms (i.e., tiredness, stiff neck, yawning, and hunger) hours or days before the headache phase [20, 21]. To the best of our knowledge, the effects of anti-CGRP monoclonal antibodies for the treatment of non-headache symptoms have been assessed in clinical studies, but not in real-world settings [22, 23].
This study evaluated the efficacy and safety of galcanezumab in real-world settings in Japan. We also assessed the effects of galcanezumab on migraine-associated symptoms and premonitory symptoms.
Methods
Study design
We conducted a single-center, observational, retrospective, cohort study. The observation period was 3 months (3 M). This study was approved by the Ethics Committee of the Keio University School of Medicine (approval number: 20211144), Tokyo, Japan. Patients were informed about this observational study via the institute’s website, and they could opt out of the study. The need for informed consent was waived by the Ethics Committee of the Keio University School of Medicine, in accordance with national regulations (Ethical Guidelines for Medical and Biological Research Involving Human Subjects). All methods were carried out in accordance with relevant guidelines and regulations.
Patients
The inclusion criteria were as follows: receipt of three doses of galcanezumab (240 mg/120 mg/120 mg) monthly from the headache group of the Keio University Hospital between August 2021 (when the drug became available at the hospital) and February 2022; fulfillment of the diagnostic criteria for migraine (including probable migraine) according to the International Classification of Headache Disorders, 3rd edition (ICHD-3) [24]; and age > 18 years. Patients were diagnosed with migraine by a headache specialist (TT). Three patients were excluded from the study owing to the discontinuation of galcanezumab before completing three doses due to side effects (lightheadedness, hair loss, and eczema).
Research items
We retrospectively collected demographic data (age, sex, height, and weight), medical history, and the following headache characteristics: age at onset, family history of headache, migraine characteristics (unilateral pain, pulsating pain, or aggravation by routine physical activity), and the presence of aura. The Generalized Anxiety Disorder-7 (GAD-7) [25, 26] and Patient Health Questionnaire-9 (PHQ-9) [27] were assessed upon administration of anti-CGRP monoclonal antibodies to determine the extent of anxiety and depression, respectively. We also collected patients’ migraine-preventive drug data, including drugs administered (lomerizine, propranolol, valproate, amitriptyline, or topiramate), use or non-use of preventive drugs at the first dosage, and handling of preventive drugs at the first dose (discontinuation or continuation).
The headache specialist (TT) explained the criteria for migraine based on the ICHD-3 to all patients, who were asked to track their headache and migraine days (including probable migraine days). Patients completed a questionnaire on the monthly migraine days (MMDs), monthly headache days (MHDs), monthly acute medication intake days (AMDs), pain intensity (0–10 Numerical Rating Scale; NRS), and associated symptoms (photophobia, phonophobia, and nausea/vomiting; none, mild, moderate, and severe) at baseline and after the first, second, and third months. The headache specialist verified the accuracy and reliability of the completed questionnaire by interviewing and occasionally reviewing each patient’s headache diary.
Patients were classified as having EM or CM according to the ICHD-3. Patients were also diagnosed with medication overuse headache (MOH) based on the ICHD-3.
Information on the injection site (forearm or abdomen), injection site reaction (pain, redness, swelling, numbness, or others) and severity (mild, moderate, or severe based on the patient’s own perspective), and other adverse reactions were also collected in the questionnaire.
Patients were asked about their satisfaction level (very satisfied, somewhat satisfied, or not satisfied) and premonitory symptoms (whether they had premonitory symptoms without subsequent headache) 3 M after receiving galcanezumab.
Outcomes
We investigated the efficacy and safety of the therapy. As for efficacy, we investigated changes in the MMD, MHD, NRS, AMD, associated symptoms, and premonitory symptoms. We also analyzed the satisfaction level with galcanezumab administration.
The primary endpoints were a change in the MMD from baseline and 50% responder rate (RR). The 50% RR was calculated as the percentage of patients with MMD reduction from baseline by ≥ 50%. The secondary endpoints were changes from baseline in the MHD; NRS; AMD; 25%, 75%, and 100% RR; associated symptoms; premonitory symptoms; and satisfaction level with galcanezumab.
For safety, we investigated the injection site, injection site reaction, and other adverse reactions.
Statistical analysis
Data are presented as number (percent) and mean ± standard deviation. Differences from baseline in MMD, MHD, AMD, and NRS and the least-squares means of them were analyzed using the mixed-effect model for repeated measures with time as a fixed effect and individual as a random effect, and the correlation structure was defined as unstructured. Normality was visually assessed using residual plots. The chi-squared test was used to compare the categorical data in the subgroup analysis. P-values for comparisons of differences from baseline were adjusted using the Bonferroni correction. We excluded missing data. All two-sided p-values < 0.05 were considered statistically significant. Statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Baseline characteristics
Fifty-two patients older than 18 years old were diagnosed with migraine by the headache specialist (TT) and received three doses of galcanezumab during the study period. The vast majority of the patients were women, and the mean age was 48.3 ± 12.9 (range, 19–81) years. At baseline, approximately half of the patients were classified as having EM. The mean MMD, MHD, and AMD were 12.6 ± 7.5 days/month, 15.6 ± 8.0 days/month, and 9.7 ± 7.0 days/month, respectively, and 30.8% patients were diagnosed with MOH. The NRS was 6.5 ± 1.5. Approximately half of the patients had premonitory symptoms (Table 1).
Table 1.
Demographic and clinical characteristics of patients
| Characteristics | EM (n = 25) | CM (n = 27) | All (n = 52) |
|---|---|---|---|
| Age, years | 51.1 ± 13.3 | 45.7 ± 12.2 | 48.3 ± 12.9 |
| Sex, female | 23 (92.0) | 23 (85.2) | 46 (88.5) |
| BMI, kg/m2 | 21.3 ± 3.1 | 20.6 ± 2.6 | 21.0 ± 2.8 |
| Onset, years | 23.9 ± 11.9 | 24.2 ± 13.3 | 24.1 ± 12.5 |
| Disease history, years | 27.2 ± 17.8 | 21.5 ± 13.2 | 24.3 ± 15.7 |
| NRS | 6.2 ± 1.4 | 6.7 ± 1.5 | 6.5 ± 1.5 |
| Migraine characteristics | |||
| Unilateral pain | 18 (72.0) | 19 (70.4) | 37 (71.2) |
| Pulsating pain | 16 (64.0) | 19 (70.4) | 35 (67.3) |
| Aggravation by routine physical activity | 18 (72.0) | 21 (77.8) | 39 (75.0) |
| MMD | 7.2 ± 2.8 | 17.6 ± 7.2 | 12.6 ± 7.5 |
| MHD | 8.6 ± 3.8 | 22.0 ± 4.7 | 15.6 ± 8.0 |
| AMD | 7.0 ± 3.3 | 12.2 ± 8.6 | 9.7 ± 7.0 |
| Medication-overuse headache | 0 (0.0) | 16 (59.3) | 16 (30.8) |
| Premonitory symptomsa | 11 (44.0) | 13 (50.0) | 24 (47.1) |
| Aura | 5 (20.0) | 7 (25.9) | 12 (23.1) |
| Associated symptoms | |||
| Photophobia | 20 (80.0) | 21 (77.8) | 41 (78.8) |
| Phonophobia | 16 (64.0) | 22 (81.5) | 38 (73.1) |
| Nausea/vomiting | 18 (72.0) | 21 (77.8) | 39 (75.0) |
| Medical history | |||
| Psychiatric | 5 (20.0) | 11 (40.7) | 16 (30.8) |
| Gastrointestinal | 4 (16.0) | 4 (14.8) | 8 (15.4) |
| Vascular | 2 (8.0) | 2 (7.4) | 4 (7.7) |
| Hormonal | 1 (4.0) | 4 (14.8) | 5 (9.6) |
| Cancer | 3 (12.0) | 2 (7.4) | 5 (9.6) |
| Respiratory | 4 (16.0) | 4 (14.8) | 8 (15.4) |
| Immuno—rheumatologic | 2 (8.0) | 3 (11.1) | 5 (9.6) |
| Hypertension | 2 (8.0) | 1 (3.7) | 3 (5.8) |
| Dyslipidemia | 4 (16.0) | 5 (18.5) | 9 (17.3) |
| Diabetes mellitus | 0 (0.0) | 1 (3.7) | 1 (1.9) |
| GAD-7 ≥ 5 | 11 (44.0) | 15 (55.6) | 26 (50.0) |
| GAD-7 ≥ 10 | 1 (4.0) | 1 (3.7) | 2 (3.8) |
| PHQ-9 ≥ 5 | 13 (52.0) | 19 (70.4) | 32 (61.5) |
| PHQ-9 ≥ 10 | 4 (16.0) | 4 (14.8) | 8 (15.4) |
| Family history of headache | 9 (36.0) | 16 (59.3) | 25 (48.1) |
Data are presented as n (%) or mean ± standard deviation
aWe excluded one patient with CM with missing data
EM Episodic migraine, CM Chronic migraine, BMI Body mass index, NRS Numerical rating scale, MMD Monthly migraine day, MHD Monthly headache day, AMD Monthly acute medication intake day, GAD-7 General anxiety disorder-7, PHQ-9 9-item Patient Health Questionnaire
Preventive drugs
In terms of previous use of other migraine preventive, 30 (57.7%), 11 (21.2%), 36 (69.2%), 19 (36.5%), and 10 (19.2%) patients received lomerizine, propranolol, valproate, amitriptyline, and topiramate, respectively. Thirty-four (46.2%) patients used only one preventive drug, and the mean number of previous migraine preventives used was 2.0 ± 1.3. Twenty-five (48.1%) patients were using migraine preventives at the time of initiating galcanezumab. Three (12%) of the relevant patients discontinued consumption of migraine preventives at the first dose and 22 (88%) continued consuming them (Table 2).
Table 2.
Preventive drugs used in studied patients
| EM (n = 25) | CM (n = 27) | All (n = 52) | |
|---|---|---|---|
| Types of migraine preventives | |||
| Lomerizine | 15 (60.0) | 15 (55.6) | 30 (57.7) |
| Propranolol | 6 (24.0) | 5 (18.5) | 11 (21.2) |
| Valproate | 18 (72.0) | 18 (66.7) | 36 (69.2) |
| Amitriptyline | 9 (36.0) | 10 (37.0) | 19 (36.5) |
| Topiramate | 3 (12.0) | 7 (25.9) | 10 (19.2) |
| Number of previous migraine preventives | |||
| 1 | 9 (36.0) | 15 (55.6) | 24 (46.2) |
| 2 | 9 (36.0) | 4 (14.8) | 13 (25.0) |
| 3 | 4 (16.0) | 3 (11.1) | 7 (13.5) |
| ≥ 4 | 3 (12.0) | 5 (18.5) | 8 (15.4) |
| Mean | 2.0 ± 1.2 | 2.0 ± 1.4 | 2.0 ± 1.3 |
| Use of migraine preventives at the first dosage | |||
| No | 9 (36.0) | 18 (66.7) | 27 (51.9) |
| Yes | 16 (64.0) | 9 (33.3) | 25 (48.1) |
| Discontinued | 3 (12.0) | 0 (0.0) | 3 (5.8) |
| Continued | 13 (52.0) | 9 (33.3) | 22 (42.3) |
Data are presented as n (%) or mean ± standard deviation
The migraine preventives we assessed were lomerizine, propranolol, valproate, amitriptyline, and topiramate
EM Episodic migraine, CM Chronic migraine
Efficacy of galcanezumab for headache
All
At baseline, an average MMD of 12.6 ± 7.5 days/month was recorded. Compared with baseline, MMD decreased by 4.9 days (95% confidence interval [CI], 3.5–6.4; p < 0.001) at 1 month (1 M), 4.9 days (95% CI, 3.2–6.6; p < 0.001) at 2 months (2 M), and 5.9 days (95% CI, 4.2–7.7; p < 0.001) at 3 M). The MHD, AMD, and NRS were also significantly reduced at 1 M compared with baseline (Fig. 1, Supplementary Fig. 1).
Fig.1.
Changes in MMD, MHD, AMD, and NRS. Line graphs are expressed as mean. Blue, green, and orange lines represent EM, CM, and ALL respectively. Please note Supplementary Fig. 1 for significant change and 95% CI. MMD, monthly migraine day; MHD, monthly headache day; AMD, monthly acute medication intake days; NRS, numerical rating scale; EM, episodic migraine; CM, chronic migraine; ALL, all patients; 1 M, 1 month; 2 M, 2 months; 3 M, 3 months
The 50% RR was 42.3% (95% CI, 28.7–56.8) at 1 M, 46.2% (95% CI, 32.2–60.5) at 2 M, and 61.5% (95% CI, 47.0–74.7) at 3 M; a 100% RR was observed in 9.6% of patients at 3 M (Fig. 2).
Fig. 2.
Responder rates. Proportion of patients with responder rates of 25%, 50%, 75%, and 100% based on monthly migraine days. EM, episodic migraine; CM, chronic migraine; ALL, all patients; RR, responder rate
Episodic migraine
At baseline, an average MMD of 7.2 ± 2.8 days/month was recorded in those with EM. Compared with baseline, MMD decreased by 3.5 days (95% CI, 2.4–4.6; p < 0.001) at 1 M, 3.3 days (95% CI, 2.2–4.5; p < 0.001) at 2 M, and 4.4 days (95% CI, 3.4–5.4; p < 0.001) at 3 M. The MHD, AMD, and NRS were also significantly reduced at 1 M compared with baseline (Fig. 1, Supplementary Fig. 1).
The 50% RR was 52.0% (95% CI, 31.3–72.2) at 1 M, 56.0% (95% CI, 34.9 ~ 75.6) at 2 M, and 76.0% (95% CI, 54.9–90.6) at 3 M; a 100% RR was observed in 20.0% of patients at 3 M (Fig. 2).
Chronic migraine
At baseline, an average MMD of 17.6 ± 7.2 days/month was recorded in those with CM. Compared with baseline, MMD decreased by 6.3 days (95% CI, 3.7–8.9; p < 0.001) at 1 M, 6.4 days (95% CI, 3.4–9.4; p < 0.001) at 2 M, and 7.3 days (95% CI, 4.0–10.6; p < 0.001) at 3 M. The MHD, AMD, and NRS were also significantly reduced at 1 M compared with baseline (Fig. 1, Supplementary Fig. 1).
The 50% RR was 33.3% (95% CI, 16.5–54.0) at 1 M, 37.0% (95% CI, 19.4–57.6) at 2 M, and 48.1% (95% CI, 28.7–68.1) at 3 M; a 100% RR was observed in only two patients (7.4%) at 2 M, but not at 3 M (Fig. 2).
Patients with or without medication-overuse headache and anxiety
Supplementary Figs. 2 and 3 show the 50% RR of the subgroup analysis of MOH and non-MOH and GAD-7 ≥ 5 and GAD-7 < 5, respectively. Although the difference was not statistically significant, non-MOH patients tended to have a higher 50% RR compared to MOH patients at 3 M (p = 0.079). There was no tendency in the 50% RR between GAD-7 ≥ 5 and GAD-7 < 5 at 3 M.
Associated symptoms
The severity of the associated symptoms (photophobia, phonophobia, nausea, and vomiting) at baseline and post-treatment are presented in Supplementary Fig. 4. We defined improvement in associated symptoms as a reduction in the severity of the symptoms. An improvement in photophobia was recorded in 45.9% (95% CI, 29.5–63.1), 62.2% (95% CI, 44.8–77.5), and 64.9% (95% CI, 47.5–79.8) of patients at 1 M, 2 M, and 3 M, respectively. An improvement in phonophobia was recorded in 35.3% (95% CI, 19.7–53.5), 47.1% (95% CI, 29.8–64.9), and 50.0% (95% CI, 32.4–67.6) of patients at 1 M, 2 M, and 3 M, respectively. An improvement in nausea/vomiting was recorded in 52.8% (95% CI, 35.5–69.6), 61.1% (95% CI, 43.5–76.9), and 63.9% (95% CI, 46.2–79.2) at 1 M, 2 M, and 3 M, respectively. Among patients with symptoms at baseline, photophobia, phonophobia, and nausea/vomiting disappeared in 24.3% (95% CI, 11.8–41.2), 26.5% (95% CI, 12.9–44.4), and 47.2% (95% CI, 30.4–64.5) of patients, respectively, at 3 M (Fig. 3).
Fig. 3.
Improvement in and disappearance of the associated symptoms. (A) Photophobia, (B) Phonophobia, and (C) Nausea/vomiting
Supplementary Fig. 5 shows how each associated symptom improved or disappeared in the MMD responder group (≥ 50% RR) or non-responder (< 50% RR) group at 3 M. Although the number did not reach significance in p-value, responders showed a higher percentage of improvement and disappearance for each associated symptom numerically compared to non-responders.
Premonitory symptoms
Twenty-four (46.1%) patients had premonitory symptoms at baseline; among them, 15 (62.5%) reported premonitory symptoms without subsequent headache after three doses of galcanezumab.
Safety
Most patients opted to receive the second and third dose in the upper arm (Table 3A). Fourteen (26.9%), nine (17.3%), and ten (20.0%) patients showed injection site reactions at the first, second, and third injections, respectively. During the three doses of galcanezumab, 18 (34.6%) patients had at least one episode of injection site reaction. The injection site reactions were mild to moderate, except in one patient who experienced severe redness and swelling (Table 3B). Pain was the most commonly reported injection site reaction (Table 3C).
Table 3.
Injection site and injection site reaction after galcanezumab
| (A) Injection site | ||||||
| Dose | Abdomen | Forearm | n | |||
| First | 52 (100) | 51 (98.1) | 52 | |||
| Second | 14 (27.5) | 37 (72.5) | 51 | |||
| Third | 14 (28.0) | 36 (72.0) | 50 | |||
| (B) Degree of injection site reaction | ||||||
| Dose | None | Mild | Moderate | Severe | n | |
| First | 38 (73.1) | 11 (21.2) | 3 (5.8) | 0 (0.0) | 52 | |
| Second | 43 (82.7) | 8 (15.4) | 1 (1.9) | 0 (0.0) | 52 | |
| Third | 40 (80.0) | 9 (18.0) | 0 (0.0) | 1 (2.0) | 50 | |
| (C) Types of injection site reaction | ||||||
| Dose | Pain | Redness | Swelling | Numbness | Others | n |
| First | 11 (21.2) | 2 (3.8) | 3 (5.8) | 0 (0.0) | 5 (9.6) | 52 |
| Second | 7 (13.5) | 4 (7.7) | 4 (7.7) | 0 (0.0) | 1 (1.9) | 52 |
| Third | 8 (16.0) | 5 (10.0) | 2 (4.0) | 0 (0.0) | 1 (2.0) | 50 |
Data are presented as n (%)
Adverse events other than injection site reactions were constipation (n = 4, 7.7%), fatigue (n = 3, 5.8%), burning sensation (n = 2, 3.8%), lightheadedness (n = 2, 3.8%), and others (n = 10, 19%) (Table 4).
Table 4.
Other adverse events
| Adverse event | n (%) |
|---|---|
| Constipation | 4 (7.7) |
| Fatigue | 3 (5.8) |
| Burning sensation | 2 (3.8) |
| Lightheadedness | 2 (3.8) |
| Urticaria | 1 (1.9) |
| Loss of hair | 1 (1.9) |
| Stiffness in the leg | 1 (1.9) |
| Chills | 1 (1.9) |
| Eczema | 1 (1.9) |
| Elevated blood pressure | 1 (1.9) |
| Menstrual irregularity | 1 (1.9) |
| Back pain | 1 (1.9) |
| Somnolence | 1 (1.9) |
| Headache | 1 (1.9) |
Data are presented as n (%)
Satisfaction level
In patients who received the three doses of galcanezumab, 21 (42.0%) were very satisfied with the therapy, 20 (40.0%) were somewhat satisfied, and 9 (18.0%) were not satisfied.
Discussion
To the best of our knowledge, this is the first, real-world study of galcanezumab and CGRPmAb in migraineurs from Japan to be reported in any international journal. Our results suggest that galcanezumab is effective and relatively safe in the Japanese population. In addition, galcanezumab improved migraine-associated symptoms, such as photophobia, phonophobia, and nausea/vomiting. The proportion of patients in whom nausea/vomiting disappeared was higher than that in whom the other two symptoms disappeared. However, premonitory symptoms remained in 62.5% of patients with 3 months of galcanezumab treatment.
The efficacy and safety of galcanezumab have been confirmed by randomized controlled trials such as EVOLVE-2 for EM and REGAIN for CM [6, 7]. In the EVOLVE-2 study on patients with EM, the change in MMD was -4.2 days/month, and the 50% RR was 59.3%. In the REGAIN study on patients with CM, the change in MMD was -4.8 days/month, and the 50% RR was 27.6%. A phase II CGAN clinical trial has evaluated the efficacy and safety of galcanezumab in Japanese patients with EM [4]. As for the efficacy, the change in MMD was -3.6 days/month, and the 50% RR was 49.8%. The efficacy (all: -5.9 MMD and 50% RR of 62.5%; EM: -4.4 MMD and 50% RR of 76.0%; and CM: -7.3 MMD and 50% RR of 48.1%) was better in this real-world study than that in the above clinical trials. The difference may be because there is no placebo arm and high expectations among patients in real-world settings.
Three real-world studies on galcanezumab from Italy, Spain, and South Korea have been published [9, 17, 18]. The study from Italy was a multicenter study, whereas the Spanish and South Korean studies were performed in single centers. CM was present in 79.8%, 87.1%, and 74.7% of patients in the studies from Italy, Spain, and South Korea, respectively. Only 51.9% of the patients in the present study had CM. In terms of failure of previous preventive drugs, the percentages of patients with ≥ 3 failures were 100% in Italy, 94.6% in Spain, and 76.7% in South Korea. Only 28.9% of patients in the present study had received ≥ 3 preventive drugs. Onabotulinumtoxin A was used in the previous studies (Italy, 45.4%; South Korea, 49.4%; Spain, 87.1%), but not in the current study. As for the 50% RR at 3 M, for high-frequency EM (HFEM), the 50% RR was 67.6%, and for CM, it was 66.7% in the Italian, 51.6% in the Spanish, and 44.8% in the South Korean study. The 50% RRs for patients in the Spanish and South Korean studies were similar to that for patients with CM in the present study (48.1%). This is probably due to the high proportion of patients with CM in the Spanish and South Korean studies. A comparison of the 50% RR for patients with HFEM in the Italian study with patients with EM in the present study suggested a higher efficacy in the present study (76.0% vs. 67.6%). This may be because the present study included 17 (68.0% with EM) patients with low-frequency EM as opposed to 0 (0%) patients in the Italian study.
All three associated symptoms improved in patients in the present study. Nausea and vomiting disappeared in a higher number of patients than photophobia and phonophobia (47.2% vs. 24.3% and 26.5%, respectively). A reason for this high rate of resolution of nausea and vomiting symptoms may be that the number of MMDs with nausea and vomiting at baseline was lower than that with photophobia and phonophobia in the previous study (EM, 4.7 ± 3.4 vs. 8.5 ± 3.5; CM, 8.8 ± 6.7 vs. 14.8 ± 7.3) [22]. However, we failed to track the types of associated symptoms during each attack; thus, we are unable to conclude whether the present cohort also showed a similar trend.
Approximately 50% of patients had premonitory symptoms at baseline. While the effects of galcanezumab were observed in some patients, 62.5% of the patients felt that the residual of premonitory symptoms even though subsequent headaches were inhibited, after three doses of galcanezumab. A post hoc analysis of data from clinical trials showed that galcanezumab reduced the frequency of migraine headache days with premonitory symptoms [19]; however, this study failed to assess days with premonitory symptoms without headache. The presence of residual premonitory symptoms is an interesting issue from the mechanistic viewpoint, that merits further studies.
In patients who received the three doses of galcanezumab, no serious adverse events were observed, and the most frequent adverse events were injection site reactions. However, three patients who were not included in the study owing to discontinuation of the therapy (side effects of lightheadedness, hair loss, or eczema) after the first or second visit contributed to a 94.5% continuation rate for 3 M. Nevertheless, the drug continuation rates for 3 M remained high. In our study, one patient had side-effect of eczema (mild), and another patient stopped galcanezumab before three doses due to eczema. Eczema has previously been reported in a patient on erenumab with asthma [28]. Interestingly, one of the two patients in our institute who developed eczema had a past history of asthma as well. Information on whether patients with allergic backgrounds develop such kind of adverse effect would be an interesting topic for future studies.
The satisfaction rate was also high at 82.0%. High satisfaction with anti-CGRP monoclonal antibodies has been reported in a real-world study [19]. This study also described satisfaction at 3 months. However, we did not include the satisfaction levels in the three patients who discontinued galcanezumab. Nevertheless, the satisfaction rate would still be high (74.5%) if we consider these patients.
This study has some strengths. It is the first real-world study from Japan that described the efficacy and safety of galcanezumab in migraineurs in detail. Moreover, we analyzed the migraine-associated and premonitory symptoms that have not been studied in a real-world setting. However, the study also has some limitations—small sample size, retrospective nature, single-center design, and a short 3-month observation period. The primary endpoint (migraine days) was mainly assessed with questionnaires and not by the actual headache diaries which were only checked in some cases. Thus, further research is necessary to elucidate the effects of anti-CGRP monoclonal antibodies in the Japanese population.
Conclusion
This study revealed that galcanezumab is effective and safe for the prevention of migraine in Japan. Anti-CGRP monoclonal antibody use improved the migraine-associated symptoms and even resulted in disappearance of nausea and vomiting in nearly half of the patients at 3 months. However, despite a reduction in headaches, premonitory symptoms without subsequent headaches were observed in > 50% of the patients at 3 M.
Supplementary Information
Additional file 1: Supplementary Figure 1. Changes in (A) MMD, (B) MHD, (C)AMD, and (D) NRS **～*** represents a statistically significant change. **adjusted p<0.01; ***adjusted p<0.001. Line graphs are expressed as mean and bars represent 95% CI. MMD, monthly migraine day; MHD, monthly headache day; AMD, monthly acute medication intake days; NRS, numerical rating scale; EM, episodic migraine; CM, chronic migraine; ALL, all patients; 1 M, 1 month; 2 M, 2 months; 3 M, 3 months.
Additional file 2: Supplementary Figure 2. Fifty percent responder rate in patients with or without medication-overuse headache. MOH: Medication-overuse headache. Responder rate was based on monthly migraine days.
Additional file 3: Supplementary Figure 3. Fifty percent responder rate in patients in GAD-7 < 5 and GAD-7 ≥ 5 (anxiety). GAD-7: Generalized Anxiety Disorder-7. Responder rate was based on monthly migraine days.
Additional file 4: Supplementary Figure 4. Degree of associated symptoms at baseline and after 1-3 M of galcanezumab. (A) Photophobia, (B) Phonophobia, and (C) Nausea/vomiting. 1 M: 1 month, 3 M: 3 months.
Additional file 5: Supplementary Figure 5. Improvement and disappearance in associated symptoms in patients with or without 50% responder rate in MMD. (A) Photophobia, (B) Phonophobia, and (C) Nausea/vomiting non-Res: non-responder (<50% responder rate), Res: responder (≥50% responder rate), MMD: monthlymigraine days. Responder rate was based on monthly migraine days.
Acknowledgements
None
Authors’ contributions
TT designed and conceptualized the study. TT and NW acquired the data. All authors analyzed and/or interpreted the data. TT and SO drafted the manuscript. All authors revised the manuscript for intellectual content. The authors read and approved the final manuscript.
Funding
This work was supported by JSPS KAKENHI (Grant number 22K15693 to TT).
Availability of data and materials
The datasets analyzed during the current study are available from the corresponding author on reasonable request.
Declarations
Ethics approval and consent to participate
This study was approved by Ethics Committee of the Keio University School of Medicine (approval number: 20211144). Patients were informed about this observational study via the institute’s website, and they could opt out of the study. The need for informed consent was waived by the Ethics Committee of the Keio University School of Medicine, in accordance with national regulations (Ethical Guidelines for Medical and Biological Research Involving Human Subjects). All methods were carried out in accordance with relevant guidelines and regulations.
Consent for publication
Not applicable.
Competing interests
TT serves as an advisor for Eli Lilly Japan, Otsuka, and Amgen. TT received speaker honoraria from Eli Lilly Japan, Daiichi Sankyo, Otsuka, Amgen, Kowa, Kyowa Kirin, Eisai, UCB Japan, and Santen Pharmaceutical and research funding from Eli Lilly Japan and Tsumura outside the submitted work. MS serves as an advisor for Eli Lilly Japan, Otsuka, and Amgen. MS received speaker honoraria from Eli Lilly Japan, Daiichi Sankyo, Otsuka, and Amgen and research funding from Otsuka outside the submitted work. JN received honoraria and research scholarships from Daiichi Sankyo. The remaining authors have no relevant financial or non-financial interests to disclose.
Footnotes
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Tsubasa Takizawa and Seiya Ohtani Both authors contributed equally to the study.
References
- 1.Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z, The L, Burden: the Global Campaign against Headache Migraine remains second among the world’s causes of disability, and first among young women: Findings from GBD2019. J Headache Pain. 2020;21:137. doi: 10.1186/s10194-020-01208-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Sakai F, Igarashi H. Prevalence of migraine in Japan: A nationwide survey. Cephalalgia. 1997;17:15–22. doi: 10.1046/j.1468-2982.1997.1701015.x. [DOI] [PubMed] [Google Scholar]
- 3.Edvinsson L, Goadsby PJ. Discovery of CGRP in relation to migraine. Cephalalgia. 2019;39:331–332. doi: 10.1177/0333102418779544. [DOI] [PubMed] [Google Scholar]
- 4.Sakai F, Ozeki A, Skljarevski V (2020) Efficacy and safety of galcanezumab for prevention of migraine headache in Japanese patients with episodic migraine: A phase 2 randomized controlled clinical trial. Cephalalgia Rep 3.10.1177/2515816320932573
- 5.Hirata K, Takeshima T, Sakai F, Tatsuoka Y, Suzuki N, Igarashi H, Nakamura T, Ozeki A, Yamazaki H, Skljarevski V. A long-term open-label safety study of galcanezumab in Japanese patients with migraine. Expert Opin Drug Saf. 2021;20:721–733. doi: 10.1080/14740338.2021.1866536. [DOI] [PubMed] [Google Scholar]
- 6.Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38:1442–1454. doi: 10.1177/0333102418779543. [DOI] [PubMed] [Google Scholar]
- 7.Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91:e2211–e2221. doi: 10.1212/WNL.0000000000006640. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Mulleners WM, Kim BK, Láinez MJA, Lanteri-Minet M, Pozo-Rosich P, Wang S, Tockhorn-Heidenreich A, Aurora SK, Nichols RM, Yunes-Medina L, Detke HC. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2020;19:814–825. doi: 10.1016/S1474-4422(20)30279-9. [DOI] [PubMed] [Google Scholar]
- 9.Kwon S, Gil YE, Lee MJ. Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients. Cephalalgia. 2022;42:705–714. doi: 10.1177/03331024221076481. [DOI] [PubMed] [Google Scholar]
- 10.Ministry of Health, Labour and Welfare (published 2021) Guidelines for promotion of optimal use of galcanezumab. Accessed 29 May 2022. https://www.pmda.go.jp/files/000240429.pdf
- 11.Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, Martelletti P. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20:6. doi: 10.1186/s10194-018-0955-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Nichols R, Skljarevski V, Dell’Agnello G, Hundemer HP, Aurora SK. Letter to the editor regarding European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20:22. doi: 10.1186/s10194-019-0975-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Diener HC, Förderreuther S, Gaul C, Giese F, Hamann T, Holle-Lee D, Jürgens TP, Kamm K, Kraya T, Lampl C, May A, Reuter U, Scheffler A, Tfelt-Hansen P (2020) Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor: Addition to the S1 guideline: Therapy of migraine attacks and prevention of migraine. Recommendations of the Germany Society of neurology and the German Migraine and headache Society. Neurol Res Pract 2:11. 10.1186/s42466-020-00057-1 [DOI] [PMC free article] [PubMed]
- 14.American Headache Society The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59:1–18. doi: 10.1111/head.13456. [DOI] [PubMed] [Google Scholar]
- 15.Alex A, Vaughn C, Rayhill M. Safety and tolerability of 3 CGRP monoclonal antibodies in practice: A retrospective cohort study. Headache. 2020;60:2454–2462. doi: 10.1111/head.13956. [DOI] [PubMed] [Google Scholar]
- 16.Vernieri F, Altamura C, Aurilia C, Brunelli N, Egeo G, Fofi L, Costa CM, Fallacara A, Favoni V, Pierangeli G, Aguggia M, Bertuzzo D, Albanese M, Di Fiore P, Frediani F, Cevoli S, Barbanti P. Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study) Neurol Sci. 2020;41:487–488. doi: 10.1007/s10072-020-04669-y. [DOI] [PubMed] [Google Scholar]
- 17.Torres-Ferrús M, Gallardo VJ, Alpuente A, Caronna E, Gine-Cipres E, Pozo-Rosich P. The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: A real-world evidence observational study. J Neurol. 2021;268:3789–3798. doi: 10.1007/s00415-021-10523-8. [DOI] [PubMed] [Google Scholar]
- 18.Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, Fofi L, Favoni V, Pierangeli G, Lovati C, Aguggia M, d’Onofrio F, Doretti A, Di Fiore P, Finocchi C, Rao R, Bono F, Ranieri A, Albanese M, Cevoli S, Barbanti P, GARLIT Study Group Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: A multicenter prospective cohort study (the GARLIT study) J Headache Pain. 2021;22:35. doi: 10.1186/s10194-021-01247-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.López-Bravo A, Oliveros-Cid A, Sevillano-Orte L. Treatment satisfaction with calcitonin gene-related peptide monoclonal antibodies as a new patient-reported outcome measure: A real-life experience in migraine. Acta Neurol Scand. 2022;145:669–675. doi: 10.1111/ane.13599. [DOI] [PubMed] [Google Scholar]
- 20.Giffin NJ, Ruggiero L, Lipton RB, Silberstein SD, Tvedskov JF, Olesen J, Altman J, Goadsby PJ, Macrae A. Premonitory symptoms in migraine: An electronic diary study. Neurology. 2003;60:935–940. doi: 10.1212/01.wnl.0000052998.58526.a9. [DOI] [PubMed] [Google Scholar]
- 21.Kelman L, Tanis D. The relationship between migraine pain and other associated symptoms. Cephalalgia. 2006;26:548–553. doi: 10.1111/j.1468-2982.2006.01075.x. [DOI] [PubMed] [Google Scholar]
- 22.Ament M, Day K, Stauffer VL, Skljarevski V, Rettiganti M, Pearlman E, Aurora SK. Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine. J Headache Pain. 2021;22:6. doi: 10.1186/s10194-021-01215-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Silberstein SD, Rapoport AM, Loupe PS, Aycardi E, McDonald M, Yang R, Bigal ME. The effect of beginning treatment with Fremanezumab on headache and associated symptoms in the randomized Phase 2 study of high frequency episodic migraine: Post-hoc analyses on the first 3 weeks of treatment. Headache. 2019;59:383–393. doi: 10.1111/head.13446. [DOI] [PubMed] [Google Scholar]
- 24.Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38:1–211. 10.1177/0333102417738202 [DOI] [PubMed]
- 25.Muramatsu K, Seiryo N, Muramatsu Y, Miyaoka H, Fuse K, Yoshine F, Hosaka M, Katagiri A, Kutumi R (2009) Validation and utility of Japanese version of the GAD-7. PANMINERVA Medica. Abstracts Book, vol 51 20th World Congress on Psychosomatic Medicine, p 79
- 26.Doi S, Ito M, Takebayashi Y, Muramatsu K, Horikoshi M. Factorial validity and invariance of the 7-item generalized anxiety disorder scale (GAD-7) among populations with and without self-reported psychiatric diagnostic status. Front Psychol. 2018;9:1741. doi: 10.3389/fpsyg.2018.01741. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Muramatsu K, Miyaoka H, Kamijima K, Muramatsu Y, Tanaka Y, Hosaka M, Miwa Y, Fuse K, Yoshimine F, Mashima I, Shimizu N, Ito H, Shimizu E. Performance of the Japanese version of the Patient Health Questionnaire-9 (J-PHQ-9) for depression in primary care. Gen Hosp Psychiatry. 2018;52:64–69. doi: 10.1016/j.genhosppsych.2018.03.007. [DOI] [PubMed] [Google Scholar]
- 28.Ray JC, Allen P, Bacsi A, Bosco JJ, Chen L, Eller M, Kua H, Lim LL, Matharu MS, Monif M, Ruttledge M, Stark RJ, Hutton EJ. Inflammatory complications of CGRP monoclonal antibodies: a case series. J Headache Pain. 2021;22:121. doi: 10.1186/s10194-021-01330-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Additional file 1: Supplementary Figure 1. Changes in (A) MMD, (B) MHD, (C)AMD, and (D) NRS **～*** represents a statistically significant change. **adjusted p<0.01; ***adjusted p<0.001. Line graphs are expressed as mean and bars represent 95% CI. MMD, monthly migraine day; MHD, monthly headache day; AMD, monthly acute medication intake days; NRS, numerical rating scale; EM, episodic migraine; CM, chronic migraine; ALL, all patients; 1 M, 1 month; 2 M, 2 months; 3 M, 3 months.
Additional file 2: Supplementary Figure 2. Fifty percent responder rate in patients with or without medication-overuse headache. MOH: Medication-overuse headache. Responder rate was based on monthly migraine days.
Additional file 3: Supplementary Figure 3. Fifty percent responder rate in patients in GAD-7 < 5 and GAD-7 ≥ 5 (anxiety). GAD-7: Generalized Anxiety Disorder-7. Responder rate was based on monthly migraine days.
Additional file 4: Supplementary Figure 4. Degree of associated symptoms at baseline and after 1-3 M of galcanezumab. (A) Photophobia, (B) Phonophobia, and (C) Nausea/vomiting. 1 M: 1 month, 3 M: 3 months.
Additional file 5: Supplementary Figure 5. Improvement and disappearance in associated symptoms in patients with or without 50% responder rate in MMD. (A) Photophobia, (B) Phonophobia, and (C) Nausea/vomiting non-Res: non-responder (<50% responder rate), Res: responder (≥50% responder rate), MMD: monthlymigraine days. Responder rate was based on monthly migraine days.
Data Availability Statement
The datasets analyzed during the current study are available from the corresponding author on reasonable request.